Corbion N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSNVY research report →
Price Chart
About the company
Corbion N. V. is a global enterprise that manufactures and supplies a diverse range of ingredients, all sourced from renewable materials.
- CEO
- Olivier Rigaud
- IPO
- 2011
- Employees
- 2,408
- HQ
- Amsterdam, NH, NL
Get TickerSpark's AI analysis on CSNVY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.71B
- P/E
- 24.26
- PEG
- -2.86
- P/S
- 1.21
- P/B
- 2.00
- EV/EBITDA
- 10.68
- Div Yield
- 3.82%
- Gross Margin
- 25.05%
- Op Margin
- 7.59%
- Net Margin
- 4.96%
- ROE
- 8.30%
- ROIC
- 5.67%
Latest fiscal year · YoY change
- Revenue
- $1.27B-1.6%
- Gross Profit
- $330.30M+5.8%
- Op Income
- $115.36M
- Net Income
- $71.85M-62.6%
- EPS
- $1.24-62.3%
- OCF Growth
- -16.1%
- FCF Growth
- -10.9%
- 52W High
- $30.31
- 52W Low
- $20.44
- 50D MA
- $27.16
- 200D MA
- $23.85
- Beta
- 0.81
- RSI (14)
- 80
- Avg Volume
- 62
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Corbion said Q3 delivered volume-led growth and a sharp profitability step-up, while reaffirming full-year guidance and keeping its PLA business in the group.· October 28, 2026
- Q3 was described as a strong quarter, with volume-led growth in both segments and a significant improvement in profitability.
- Health & Nutrition was the main driver, helped by a sharp recovery in Nutrition volumes, stronger Omega-3 DHA pricing and new customer wins.
- Functional Ingredients & Solutions grew on natural preservation, enzymes and biochemicals, but Q4 margin should be seasonally lower due to sulfuric acid costs tied to the Middle East conflict.
- Corbion abandoned the sale process for its TotalEnergies Corbion PLA JV, saying bids did not reflect the business’s value and long-term potential.
- Full-year guidance was unchanged: 3% to 6% organic sales growth, adjusted EBITDA margin above 16%, and free cash flow of EUR 85 million to EUR 90 million.
Management said Q3 2026 delivered strong growth and a significant step-up in profitability, but did not state company-wide revenue, EPS or gross margin figures on the call. In Health & Nutrition, H1 margin was described as around 27%, Q3 margin as 38%, and management said Q4 should be broadly in line with Q3; for the longer term they still expect around 30% in H&N, with some volatility. For Functional Ingredients & Solutions, year-to-date margin was said to be 15.7%, and management expects the full-year margin to end above 16%, though Q4 should be seasonally lower and slightly more pressured than last year because of sulfuric acid. Free cash flow year to date was EUR 57 million, and the full-year free cash flow target remains EUR 85 million to EUR 90 million; full-year outlook is unchanged at 3% to 6% organic sales growth and adjusted EBITDA margin above 16%.
Olivier Rigaud framed the quarter as evidence that Corbion’s growth and profitability mix is improving, with growth now increasingly volume-driven and supported by cost actions and operational efficiency. He repeatedly emphasized that the business has better visibility into Q4 and that the company is staying disciplined on pricing, capacity planning and cash conversion. On PLA, he said the sale process was stopped because offers did not reflect the asset’s value, and that the business will remain noncore but be developed under the current structure to maximize shareholder value.
Peter Kazius said the biggest financial progression came in Health & Nutrition, where Q3 margin reached 38% after an H1 level of around 27%, and he expects Q4 to stay around that level. He noted that the H&N pricing picture is tied to shorter-term contracts with 3 to 6 months’ visibility, while the long-term margin expectation remains around 30% with volatility. On cash, he said 9-month free cash flow of EUR 57 million supports the full-year target, and he reiterated the company’s focus on disciplined capex and cash conversion. For FINS, he pointed to a margin mix of sugar being positive, sulfuric acid and the Middle East becoming more negative, and cost/pricing helping offset that.
Analysts focused heavily on why H&N margins were not stepping up further despite higher fish oil prices, and management explained that the business is deliberately minimizing spot exposure and prioritizing longer-term contracts and strategic customers. They said the Q3 pricing picture was affected by customer mix and commercial terms, not just index moves, and that Q4 should look broadly similar to Q3 before reopening the margin question for 2027 contract renewals. Questions on the Middle East cost headwind were met with a figure of EUR 26 million annualized impact, which management said is expected to persist into 2027 and will be partly mitigated through January pricing actions. Analysts also pressed on the PLA JV sale and on rumored M&A speculation; management said PLA remains noncore but the sale was halted because bids were too low, and they declined to comment on rumors.
The call pointed to improving underlying momentum, with volume-led growth across both segments and a clear rebound in profitability as cost actions, lower sugar costs and better operational efficiency flowed through. Management also said Q4 visibility is good and reaffirmed full-year targets, while highlighting healthier H&N economics, stronger PLA pricing momentum and strong cash generation.
The main risks on the call were the structural sulfuric acid headwind from the Middle East conflict, which management quantified at EUR 26 million annualized and expects to continue into 2027, and the lower Q4 margin expected in FINS. Management also signaled that H&N margins will not necessarily keep stepping up because contract timing and fish oil volatility create volatility, while pharma remains soft and PLA is still noncore despite better pricing trends.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 57.65M
- Float Shares
- 57.34M
Our CSNVY coverage
Recent articles, reports, and earnings notes.
No research on CSNVY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSNVY report →Corbion N.V. (CSNVY) Discusses Innovation Platform Supporting BRIGHT 2030 Growth Strategy Transcript
seekingalpha.com · Nov 11
Corbion N.V. (CSNVY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 28
Corbion N.V. (CSNVY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 5
Corbion N.V. (CSNVY) Q1 2026 Earnings Call Transcript
seekingalpha.com · Apr 22
Corbion N.V. (CSNVY) Q4 2025 Earnings Call Transcript
seekingalpha.com · Mar 2
Corbion N.V. (CSNVY) Analyst/Investor Day Transcript
seekingalpha.com · Nov 21
Corbion reports the progress of its share buyback program 6 October – 10 October 2025
globenewswire.com · Oct 13
Corbion reports the progress of its share buyback program 29 September – 3 October 2025
globenewswire.com · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.